Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

NCT ID: NCT03193502

Last Updated: 2017-10-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

-Rivaroxaban is factor Xa inhibitor

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PVT is a common complication of liver cirrhosis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Portal Vein Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Portal Vein thrombosis

rivaroxaban

Group Type EXPERIMENTAL

rivaroxaban

Intervention Type DRUG

rivaroxaban

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rivaroxaban

rivaroxaban

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

xarelto

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute PVT

Exclusion Criteria

* Malignant PVT
* Bleeding disorders
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sherief Abd-Elsalam

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sherief Abd-Elsalam

Consultant

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amr Hanafy, Professor

Role: PRINCIPAL_INVESTIGATOR

Hepatology unit - Zagazig University

Mohamed Basha, Consultant

Role: STUDY_DIRECTOR

Radiology Dept - Zagazig University

Sherief Abd-elsalam, consultant

Role: STUDY_CHAIR

Hepatology - Gastroenterology - Tanta University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tropical medicine dept.-Tanta university hospital

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sherief Abd-Elsalam, consultant

Role: CONTACT

Phone: 00201095159522

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sherief Abd-Elsalam

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Amr Hanafy

Identifier Type: -

Identifier Source: org_study_id